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practice. Numerous case reports documenting
pancreatitis, liver damage, leukopenia, and
thrombocytopenia [2] exist but the true incidence of
clinically significant abnormalities is not known.

Abstract
Current laboratory monitoring may not be optimal.
A retrospective chart review was performed on the
laboratory results of 246 patients who were treated
with isotretinoin for acne over a 9-year period. Tests
obtained were CBC, lipid panel, AST, ALT, CK, GGT,
and C-reactive protein. Thirty-five patients had an
elevated AST and 35 of these had an elevated CK; 32
had an elevated ALT and 11 of these had an elevated
CK. Thirteen patients had an elevated GGT; in 5 this
was the only abnormality, whereas 8 had a GGT
elevation accompanied by an elevated AST or ALT.
Two had an elevated GGT and an elevated CK with
normal AST and ALT. Fifty-two patients had a single
episode of elevated CK, of which 22 were female.
However, 57 had multiple CK elevations and only one
was female. Thirty-five patients had CK elevations <
2 times normal; 38 had levels between 2 and 3 times
normal, 18 had levels between 3 and 4 times normal,
and 18 had levels greater than 4 times normal. We
suggest that ALT and AST are not useful for monitoring
isotretinoin therapy and that GGT and CK may be of
greater value in managing patients.

Results
A retrospective chart review was performed regarding
patients treated with isotretinoin for acne between
2005 and 2014. Two hundred forty-six patients were
identified. Patient identity was protected by assigning
a code number to each individual. Laboratory tests
were done at initiation of therapy and with dosage
changes. Patients with abnormalities had monthly
testing until they resolved. Tests obtained were CBC,
lipid panel, AST, ALT, CK, GGT, and C-reactive protein.
Female patients also had HCG performed. None were
positive.
Thirty-five patients had an elevated AST and 32 of
these had an elevated CK; 32 had an elevated ALT
and 11 of these had an elevated CK. Thirteen patients
had an elevated GGT (this was the only abnormality
in 5); 8 had a GGT elevation accompanied by an
elevated AST or ALT. Two had an elevated GGT and an
elevated CK with normal AST and ALT. Five patients
had elevation of GGT on more than one visit. The vast
majority of elevations were less than twice the top
normal value. Highest levels were AST 191, ALT 118,
GGT 102.

Keywords: isotretinoin, laboratory monitoring, acne,
muscle liver

Introduction
Laboratory monitoring of patients treated with
isotretinoin is standard practice, but evaluation of
the results is confounded by choice of laboratory test.
In general the same tests as reported by the original
investigators [1] are the ones used today in clinical

Fifty-two patients had a single episode of elevated CK
of which 22 were female. However, 57 had multiple
CK elevations and only one was female. Thirty-five
patients had CK elevations less than 2 times normal;
38 had levels between 2 and 3 times normal, 18 had
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levels between 3 and 4 times normal, and 18 had
levels greater than 4 times normal.
Thirty-nine individuals had CRP elevations. Ten were
elevated at baseline and 23 had elevation at the end
of therapy. Twenty-seven patients had simultaneous
elevations of TG and CRP.
Ninety-five patients overall had elevation of TG; 26
were elevated at baseline, 45 had elevations at the
end of therapy and 15 were elevated throughout
therapy.
One hundred-eleven had elevations of cholesterol;
45 were elevated at baseline, 75 were elevated at the
end of therapy, and 35 had elevations throughout
therapy.
Twenty-one had high WBC at some point in therapy;
15 also had high ANC, two of which had a low ALC.
Thirty patients had an episode of low WBC; 14 had
low ANC, two of which had a high ALC and one
had low WBC and high ANC. Modest elevations
and depressions in hemoglobin were seen in many
patients sporadically. Sixteen patients had elevations
in platelets at some time during therapy; 6 of these
were elevated on more than one occasion. No platelet
elevation exceeded 480. Fifteen patients displayed a
low platelet count on at least one occasion during
therapy. The lowest value was 89, which returned to
normal on subsequent tests. Three patients had more
than one low level during therapy.

Case Discussion
Laboratory abnormalities during isotretinoin therapy
are thought to be a common occurrence, but there
is surprisingly little organized study regarding their
severity or consequence. Zane and colleagues
[2] studied the laboratory results of over 13,000
isotretinoin treated patients and found 11% had
modest transaminase elevations but nearly 50%
had triglyceride abnormalities at some time during
therapy. A recent study by Lee and colleagues [3]
reported on the mean elevation of blood tests and
found it to be low and suggested that routine testing
may not be cost effective.
In our practice we monitor CBC, AST, ALT, GGT, CK,
and lipids and order tests at baseline and with each

dosage change. Peak isotretinoin dosage is typically
near 1mg/kg. Tests that are abnormal are followed
until they normalize. Patients are counselled on the
significance of each abnormal test and steps that
should be taken.
AST and ALT are enzymes thought of as “liver tests”
but they are not liver-specific, being found in liver,
muscle, and other tissues including red blood cells.
GGT is a liver specific enzyme. CK is a muscle specific
enzyme. In the current study we found that AST
elevation was usually accompanied by CK elevation,
suggesting a muscle (rather than liver) source for
the AST. ALT was less strongly paired with CK but
there was some overlap. GGT elevation was much
less common and occurred only 13 times. These
findings suggest that AST and ALT are less useful
for monitoring liver damage than GGT and may be
redundant tests. In addition, the presence of AST and
ALT in red blood cells can lead to false positive values
if there is hemolysis [4].
The low incidence and severity of abnormal liver tests
(indicated by GGT level) is encouraging and suggests
that isotretinoin is not a major cause of liver injury. It
must also be noted that other events such as alcohol
ingestion or infection can cause elevations in GGT
independent of isotretinoin.
Lee et al. [3] noted the low mean severity of liver
abnormalities and suggested that measuring AST
and ALT may not be cost–effective. This report
confirms that individual liver tests (as opposed to the
mean of a large group as was measured in [3]) are
not usually abnormal and that when elevated they
are only mildly-so. Moreover we show that much of
the AST and ALT elevations appear to arise from nonliver sources.
In contrast to liver tests, muscle tests were more
commonly elevated and some to quite high levels. In
many cases the patients had no muscular symptoms
but most gave a history of vigorous exercise. Men
were at clearly greater risk of repeated elevation,
which may reflect behavior. The significance of
these abnormalities in CK is uncertain. CK elevations
greater than five times normal accompanied by
muscle pain, fatigue, and weakness can be a sign of
rhabdomyolysis, which can lead to renal damage [6].
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The patients in this study did not have CK elevations
of that magnitude.
There are two reported cases of full-blown
rhabdomyolysis in the setting of isotretinoin therapy
[7, 8] and patients treated with the drug commonly
report decreased exercise tolerance and achiness[1,
9]. Several studies have reported CK elevations from
5 to 41% in patients treated with isotretinoin [6]. We
counsel patients to avoid strenuous exercise during
therapy and await further study on the effects of
isotretinoin on muscle.

6.
7.
8.
9.

Conclusion
What tests should be used to monitor patients
treated with isotretinoin? Clearly HCG and lipids must
be monitored, and based on this chart review, CBC
appears to be of minimal value. In this population,
elevations in AST and ALT were found to not usually
be indicative of liver problems. If the liver is to be
monitored, GGT appears to be a more useful test.
Given the frequency and magnitude of CK elevations
it may be helpful, especially in the physically active,
to monitor this enzyme during isotretinoin therapy.

Abbreviations
ALC-absolute lymphocyte count
ALT-alanine aminotransferase
ANC-absolute neutrophil count
AST-aspartate aminotransferase
CBC-complete blood count
CK-creatine kinase
GGT-gamma glutamyltransferase
TG-triglyceride
WBC-white blood cell
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